Quest Pharmatech Stock Performance
| QPTFF Stock | USD 0.01 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Quest PharmaTech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Quest PharmaTech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Quest PharmaTech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 199.1 K | |
| Total Cashflows From Investing Activities | -14 K |
Quest |
Quest PharmaTech Relative Risk vs. Return Landscape
If you would invest 1.33 in Quest PharmaTech on November 11, 2025 and sell it today you would earn a total of 0.00 from holding Quest PharmaTech or generate 0.0% return on investment over 90 days. Quest PharmaTech is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Quest, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Quest PharmaTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Quest PharmaTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Quest PharmaTech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Quest PharmaTech generated a negative expected return over the last 90 days | |
| Quest PharmaTech has some characteristics of a very speculative penny stock | |
| Quest PharmaTech has accumulated 1000 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Quest PharmaTech has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Quest PharmaTech until it has trouble settling it off, either with new capital or with free cash flow. So, Quest PharmaTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quest PharmaTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quest to invest in growth at high rates of return. When we think about Quest PharmaTech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (85.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quest PharmaTech has accumulated about 518.76 K in cash with (170.78 K) of positive cash flow from operations. | |
| Roughly 17.0% of Quest PharmaTech outstanding shares are owned by corporate insiders |
Quest PharmaTech Fundamentals Growth
Quest Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Quest PharmaTech, and Quest PharmaTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quest Pink Sheet performance.
| Return On Equity | -0.62 | |||
| Return On Asset | -0.0038 | |||
| Current Valuation | 7.81 M | |||
| Shares Outstanding | 169.13 M | |||
| Price To Earning | 0.14 X | |||
| Price To Book | 0.19 X | |||
| EBITDA | (84.99 M) | |||
| Cash And Equivalents | 518.76 K | |||
| Total Debt | 1000 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.52 X | |||
| Cash Flow From Operations | (170.78 K) | |||
| Earnings Per Share | (0.39) X | |||
| Total Asset | 91.03 M | |||
About Quest PharmaTech Performance
By analyzing Quest PharmaTech's fundamental ratios, stakeholders can gain valuable insights into Quest PharmaTech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Quest PharmaTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Quest PharmaTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications skin penetrating active molecules for cosmetic and pharmaceutical use and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest Pharmatech is traded on OTC Exchange in the United States.Things to note about Quest PharmaTech performance evaluation
Checking the ongoing alerts about Quest PharmaTech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Quest PharmaTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quest PharmaTech generated a negative expected return over the last 90 days | |
| Quest PharmaTech has some characteristics of a very speculative penny stock | |
| Quest PharmaTech has accumulated 1000 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Quest PharmaTech has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Quest PharmaTech until it has trouble settling it off, either with new capital or with free cash flow. So, Quest PharmaTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quest PharmaTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quest to invest in growth at high rates of return. When we think about Quest PharmaTech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (85.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quest PharmaTech has accumulated about 518.76 K in cash with (170.78 K) of positive cash flow from operations. | |
| Roughly 17.0% of Quest PharmaTech outstanding shares are owned by corporate insiders |
- Analyzing Quest PharmaTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quest PharmaTech's stock is overvalued or undervalued compared to its peers.
- Examining Quest PharmaTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quest PharmaTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quest PharmaTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quest PharmaTech's pink sheet. These opinions can provide insight into Quest PharmaTech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Quest Pink Sheet analysis
When running Quest PharmaTech's price analysis, check to measure Quest PharmaTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest PharmaTech is operating at the current time. Most of Quest PharmaTech's value examination focuses on studying past and present price action to predict the probability of Quest PharmaTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest PharmaTech's price. Additionally, you may evaluate how the addition of Quest PharmaTech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |